Founded in 1976, this CTD dossier owner and manufacturer began as a merger of seven private pharmaceutical institutes to form a state-owned enterprise under the jurisdiction of the local health department. Over the years, it evolved to adapt to the changing economic landscape, becoming a joint stock company in 2001 as part of a broader strategy to diversify ownership and enhance business efficiency. Today, the company operates with a focus on leveraging its legacy and infrastructure to drive growth and employee investment, maintaining a strong presence in the pharmaceutical sector.
Simethicone is an anti-foaming agent that helps relieve symptoms of gas such as painful or uncomfortable or pressure, fullness, or bloating. In the digestive tract, its actions decrease the surface tension of gas bubbles, causing them to form larger bubbles. However, it is to be noted that it cannot reduce or prevent gas formation in the digestive tract. Eventually, it provides relief from symptoms of excessive gas, like bloating, burping and flatulence.
Simethicone is sold, under the Brand names like Alka-Seltzer® Anti-Gas, Colic Drops, Colicon®, Degas®, Flatulex® Drops, amongst others. Mcneil-Ppc, Inc. filed the first patent for making this medicine in 1997 for their Simethicone/ anhydrous calcium phosphate compositions. Later, Shire Laboratories, Inc. also filed for patents in 1999 followed by Panacea Biotec Ltd in 2005 for the specific formulations and preparations.While controlling or treating Flatulence, the recommended Usual Adult Dose if taking Chewable Tablets is, 80 to 160 mg, or if taking Extra Strength 125 mg Capsules, the dose is 125 to 250 mg. If taking Ultra Strength 180 mg Capsules the dose is 180 to 360 mg and when taking the Maximum Strength 250 mg Capsules the recommended dose is 250 to 500 mg, taken orally once after a meal.